Update on Affibody molecules for in vivo imaging of targets for cancer therapy

Minerva Biotecnologica

Volumn 21, Issue 1, 2009, Pages 21-30

  Tolmachev, V ^a,b,c   Orlova, A ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; HER2; Neoplams; Radionuclide imaging; Radiopharmaceuticals

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORINE 18; GALLIUM 68; TECHNETIUM 99M;

IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SCINTISCANNING;

EID: 67749127526     PISSN: 11204826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsén L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther. 2007;7:555-568 (Pubitemid 46524679)
2. Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv 2006; 3:53-70. (Pubitemid 43056391)
3. Levin AM, Weiss GA. Optimizing the affinity and specificity of proteins with molecular display. Mol Biosyst 2006;2:49-57.
4. Hosse RJ, Rothe A, Power BE. A new generation of protein display scaffolds for molecular recognition. Protein Sci 2006;15:14-27. (Pubitemid 43004229)
5. Rothe A, Hosse RJ, Power BE. In vitro display technologies reveal novel biopharmaceutics. FASEB J 2006;20:1599-1610
6. Kennel SJ, Mirzadeh S, Hurst GB, Foote LJ, Lankford TK, Glowienka KA et al Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. Nucl Med Biol 2000;27:815-825 (Pubitemid 32058821)
7. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007;18:295-304. (Pubitemid 47385180)
8. Nord K, Nilsson J, Nilsson B, Uhlen M, Nygren PA. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng 1995;8:601-608
9. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997;15:772-777 (Pubitemid 27329481)
10. Nygren PA. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008;275:2668-2676
11. Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 2007;10:167-175 (Pubitemid 46438646)
12. Orlova A, Feldwisch J, Abrahmsén L, Tolmachev V. Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 2007;22:573-584 (Pubitemid 350058993)
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137 (Pubitemid 33674041)
14. Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 2000;16:567-576
15. Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344-2348 (Pubitemid 38961898)
16. Gardmark T, Wester K, de la Torre M, Carlsson J, Malmstrom PU. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 2005;95:982-986 (Pubitemid 40655692)
17. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878
18. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol 2005;26:281-293
19. Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J et al. Selection and characterization of HER2/neubinding affibody ligands. Protein Eng Des Sel. 2004;17:455-462 (Pubitemid 39294720)
20. Mume E, Orlova A, Larsson B, Nilsson AS, Nilsson FY, Sjöberg S et al. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem 2005;16:1547-1555 (Pubitemid 41683137)
21. Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Ståhl S et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Mother Radiopharm 2005;20.239-48.
22. Orlova A, Nilsson FY, Wikman M, Widström C, Ståhl S, Carlsson J et al. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 2006;47:512-519 (Pubitemid 46768494)
23. Steffen AC, Orlova A, Wikman M, Nilsson FY, Ståhl S, Adams GP et al. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 2006;33:631-638 (Pubitemid 43846754)
24. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006;66:4339-48.
25. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006;47:846-853
26. HFR2 342, a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med 2007;20:397-404.
27. HER2 342. an affibody ligand coniugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mo Imaging 2007;51:314-323
28. Tran T, Orlova A, Sivaev I, Sandström M, Tolmachev V. Comparison of benzoate- and odecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. Int J Mol Med 2007;19:485-493
29. Orlova A. Tolmachev V, Pehrson R, Lindlborg M, Tran T, Sandström M et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007,67:2178-2186 (Pubitemid 46424237)
30. HER2 312-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med. 2007;19:285-291
31. Baum R, Orlova A, Tolmachev V, Feldwisch J. Receptor PET/CT and SPECT using an Affibody molecule for targeting and molecular imaging of HER2 positive cancer in animal xenografts and human breast cancer patients J Nucl Med 2006; 47 (Suppl 1): 108P.
32. 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007;34:722-733 (Pubitemid 46669355)
33. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 2007;34:1843-1853 (Pubitemid 47599054)
34. Tran T, Engfeldt T, Orlova A, Widström C, Bruskin A, Tolmachev V et al. in vivo evaluation of cysteine-based chelators for attachment of »mTc to tumor-targeting Affibody molecules. Bioconjug Chem 2007;18:549-558 (Pubitemid 46493528)
35. HER2 342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 2007;18:1956-1964 (Pubitemid 350219996)
36. 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging. 2008;35:2245-2255
37. Engfeldt T, Renberg B. Brumer H, Nygren PA. Karlström AE. Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein. Chembiochem 2005;6:1043-1050 (Pubitemid 40825345)
38. Lundberg E, Höidén-Guthenberg I, Larsson B, Uhlén M. Gräslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods 2007;319:53-63. (Pubitemid 46107467)
39. Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B et al. Evaluation of Maleimide Derivative of DOTA for Site-Specific Libeling of Recombinant Affibody Molecules. Bioconjug Chem 2008;19:235-243.
40. Tolmachev V, Xu H, Wållberg H, Ahlgren S, Hjertman M, Sjöberg A et al. Evaluation of maleimido derivative of CHX-A"DTPA for site-specific labeling of Affibody molecules. Bioconjugate Chem 2008;19:1579-87.
41. Liberatore M, Neri D, Neri G, Pini A, Iurilli AP, Ponzo F et al. Efficient one-step direct labelling of recombinant antibodies with technetium-99m. Eur J Nucl Med 1995;22:1326-1329
42. George AJ, Jamar F, Tai MS, Heelan BT, Adams GP, McCartney JE et al. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci U S A 1995;92:8358-8362
43. 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med 2006,47:1707-1716 (Pubitemid 47545038)
44. HER2 342 with C-terminal engineered cysteine. Eur J Nucl Med Mol Imaging 2007;34 (Suppl 2):S190.
45. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999;99:2235-2268
46. Waibel R, Alberto R, Willuda J. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 1999;17 897-901.
47. Schibli R, Schubiger PA. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med. 2002;29:1529-1542 (Pubitemid 35232058)
48. Zhu Z, Wang Y, Zhang Y, Liu G, Liu N, Rusckowski M et al. A novel and simplified route to the synthesis of N3S chelators for 99mTc labeling. Nucl Med Biol 2001;28:703-708 (Pubitemid 32772873)
49. 99mTc-labelled peptides. Q J Nucl Med 2002;46:195-205. (Pubitemid 35203313)
50. Chang F, Rusckowski M, Qu T, Hnatowich DJ. Early results in the irrational design of new bifunctional chelators. Cancer 1997;80:2347-2359 (Pubitemid 28009485)
51. Nicolas E, Pedroso E, Giralt E. Formation of Aspartimide Peptides in Asp-Gly Sequences. Tetrahedron Letters 1989;30:497-500.
52. Lundqvist H, Tolmachev V. Targeting peptides and positron emission tomography. Biopolymers 2002;66:381-392 (Pubitemid 36433533)
53. 124I-labelled Affibody molecules and transtuzumab in a murine xenograft model. J Nucl Med 2009;50:417-425
54. HFR2 342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008;35:1008-1018
55. 18F] Fluorobenzaldehyde via Oxime Chemistry. Mol Imaging Biol 2008;10:177-181
56. 18F-labeled RGD and octreotide analogs. J Nucl Med 2004;45:892-902. (Pubitemid 47618571)
57. 18F-labeled protein scaffold molecules. J Nucl Med 2008:49-804-813 (Pubitemid 351717547)